

The **first and only** chewable ADHD medication in Canada*

VYVANSE chewable tablets:
Now on the NIHB drug benefit list
(Limited use)

CHEW ON THAT!

VYVANSE is available in a child-appropriate, chewable form¹

Flexibility of 6
strawberry-flavoured,
chewable strengths:



Tablets actual size

VYVANSE dose
(*d*-amphetamine
equivalent)

10 mg
(3.0 mg)

20 mg
(5.9 mg)

30 mg
(8.9 mg)

40 mg
(11.9 mg)

50 mg
(14.8 mg)

60 mg[†]
(17.8 mg)

For starting or switching
from another stimulant[‡]

When a dose increase is warranted,
daily dose may be adjusted in
increments of 10 mg or 20 mg at
approximately weekly intervals

Administration considerations:²

- Take the entire contents of the tablet (do not divide)
- Take chewable tablets in the morning, with or without food
- Avoid taking in the afternoon as it may cause insomnia
- Chew tablet thoroughly before swallowing, with or without food or water
- Capsules can be substituted with chewable tablets on a milligram-per-milligram basis

For more information on dosing and administration, please refer to the Product Monograph.

**A convenient, easy-to-administer dosing option
for your pediatric ADHD patients**

VYVANSE (lisdexamfetamine dimesylate) capsules and chewable tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).²

* Based on the information available on the Health Canada Drug Product Database. Comparative clinical significance is unknown.

[†] In patients with severe renal insufficiency, the maximum dose should not exceed 50 mg OD AM. Further dosage reduction should be considered in patients undergoing dialysis.

[‡] Usual starting dose is 30 mg OD AM; however, when a lower dose is appropriate, treatment may begin at 20 mg OD AM. OD, once daily.



VYVANSE capsules

Trust in our ADHD experience of over 10 years^{3*}
#1 long-acting stimulant dispensed by psychiatrists across Canada⁴

How to START with

VYVANSE

Administration considerations:²

- Take the entire contents of the capsule
- Take capsules in the morning, with or without food
- Avoid taking in the afternoon as it may cause insomnia
- If mixing capsule contents with yogurt, water, or orange juice, break apart any compacted powder and consume contents immediately (do not store)

Consult the Product Monograph at www.takeda.com/en-ca/vyvanse-pm for important information on clinical use, contraindications, warnings, precautions, adverse reactions, interactions, and dosing.

The VYVANSE Product Monograph is also available by calling us at 1-800-268-2772.

* Comparative clinical significance is unknown.

† Usual starting dose is 30 mg OD AM; however, when a lower dose is appropriate, treatment may begin at 20 mg OD AM.

‡ In patients with severe renal insufficiency, the maximum dose should not exceed 50 mg OD AM. Further dosage reduction should be considered in patients undergoing dialysis.
OD, once daily.


References: 1. Ontario Pharmacists Association. Children's Medicine: Dosing, Administration, Adherence and Storage. 2019. Available at: https://www.opatoday.com/tips-and-common-questions/tip-sheets/childrens_meds. Retrieved June 24, 2019. 2. VYVANSE Product Monograph. Takeda Canada Inc. July 21, 2020. 3. Health Canada. VYVANSE Notice of Compliance Information. 2009. Available at: <https://health-products.canada.ca/noc-ac/info.do?lang=en&no=10043>. Retrieved April 10, 2019. 4. Takeda Pharmaceutical Company Limited. Data on file: IQVIA data. June 2020.

For starting or switching from another stimulant[†]


VYVANSE dose
(d-amphetamine equivalent)

Capsules actual size

10 mg (3.0 mg)




20 mg (5.9 mg)




30 mg (8.9 mg)




40 mg (11.9 mg)



50 mg (14.8 mg)



60 mg[‡] (17.8 mg)




VYVANSE offers
once-daily dosing²

When a dose increase is warranted, daily dose may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals



Tablets:
Chewable



Capsules:
Swallowable



Capsules:
Mixable with water,
orange juice, or yogurt

For ADHD, the maximum dose should not exceed 60 mg OD AM



Takeda Canada Inc.
VYVANSE[®] and the VYVANSE Logo[®] are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc.
TAKEDA[™] and the TAKEDA Logo[®] are trademarks of Takeda Pharmaceutical Company Limited, used under license.
© 2020 Takeda Pharmaceutical Company Limited. All rights reserved.
PRMCA/CA/1086 105985-09-2021-E

